

Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies

Alexander J Rodríguez  and Bo Abrahamsen 

The authors acknowledge and correct two errors.⁽¹⁾ In the Abstract and section titled “Why Is It Important to Understand the CV Benefits and Harms of Osteoporosis Medications?”, we described the anabolic agent odanacatib as a monoclonal antibody. This is incorrect, and it is in fact a chemical compound that acts to inhibit cathepsin K. In the section titled “Ongoing Uncertainty of the Cardiovascular Significance of Romosozumab,” we wrote that in patients with sclerosteosis, SOST gene mutations lead to increased sclerostin levels when in fact it leads to decreased levels. These errors do not affect our overall interpretation of the clinical experience of romosozumab in trials and uncertainty over cardiovascular risk. The authors regret any confusion and inconvenience this may have caused the readers of *JBMR Plus*.

Reference

1. Rodríguez AJ, Abrahamsen B. Cardiovascular safety of antifracture medications in patients with osteoporosis: a narrative review of evidence from randomized studies. *JBMR Plus*. 2021;5(7):e10522.

This is an open access article under the terms of the [Creative Commons Attribution](#) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Received in original form March 15, 2022; accepted March 30, 2022.

JBMR[®] Plus (WOA), Vol. 6, No. 6, June 2022, e10628.

DOI: 10.1002/jbm4.10628

© 2022 The Authors. *JBMR Plus* published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.